Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs

  |  

The authors found that a mindset of “NSAID users can choose their own dose” irrespective of dosing recommendations and poor knowledge of maximum one-time and 24-hour dosing was associated with exceeding the daily dosing limit. The approach of starting with the lowest effective dose was inversely associated with exceeding the daily dosing limit. Additionally, these characteristics are potentially modifiable.

One major limitation was the study’s low participation rate.

ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Kaufman DW, Kelly JP, Battista DR, et al. Exceeding the daily dosing limit of nonsteroidal anti-inflammatory drugs among ibuprofen users. Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):322–331. doi: 10.1002/pds.439

Related Articles

    FDA to Review Abuse-Deterrent Oxycodone Capsule

    FDA to Review Abuse-Deterrent Oxycodone Capsule In June, the FDA will discuss the New Drug Application for Remoxy ER at an Advisory Committee meeting. Remoxy ER is a 12-hour, abuse-deterrent, extended-release oxycodone in a capsule formulation.1 The capsule contains a sticky, thick, high-viscosity formulation to deter unapproved drug administration routes, including injection, smoking or snorting….

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

    Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

    Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…